Peter J. Laud

2.0k total citations
24 papers, 1.4k citations indexed

About

Peter J. Laud is a scholar working on Epidemiology, Molecular Medicine and Pharmacology. According to data from OpenAlex, Peter J. Laud has authored 24 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 5 papers in Molecular Medicine and 4 papers in Pharmacology. Recurrent topics in Peter J. Laud's work include Antibiotic Resistance in Bacteria (5 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers) and Lung Cancer Research Studies (3 papers). Peter J. Laud is often cited by papers focused on Antibiotic Resistance in Bacteria (5 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers) and Lung Cancer Research Studies (3 papers). Peter J. Laud collaborates with scholars based in United Kingdom, United States and Spain. Peter J. Laud's co-authors include J. Armstrong, Leanne B. Gasink, Greg Stone, Angela Wardman, Paul Newell, Yehuda Carmeli, Arshad Majid, Joseph W. Chow, Jie Song and Gregory G. Stone and has published in prestigious journals such as PLoS ONE, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Peter J. Laud

23 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter J. Laud United Kingdom	13	633	501	373	296	255	24	1.4k
Aryun Kim South Korea	20	345 0.5×	446 0.9×	286 0.8×	142 0.5×	93 0.4×	62	1.3k
Vincenzo Pota Italy	17	163 0.3×	173 0.3×	74 0.2×	71 0.2×	11 0.0×	74	913
Philip Giordano United States	20	90 0.1×	230 0.5×	901 2.4×	61 0.2×	48 0.2×	34	2.0k
Eric S. Donkor Ghana	8	99 0.2×	31 0.1×	347 0.9×	54 0.2×	187 0.7×	44	939
Kurt Rasche Germany	19	116 0.2×	56 0.1×	143 0.4×	45 0.2×	13 0.1×	124	1.8k
Hongke Zeng China	22	60 0.1×	92 0.2×	287 0.8×	27 0.1×	401 1.6×	77	1.3k
Marie Grill United States	12	45 0.1×	183 0.4×	103 0.3×	22 0.1×	39 0.2×	44	797
Chung‐Kan Peng Taiwan	16	88 0.1×	68 0.1×	114 0.3×	32 0.1×	29 0.1×	77	804
Jessica L. Carpenter United States	20	41 0.1×	40 0.1×	417 1.1×	17 0.1×	33 0.1×	63	1.4k
Anu Gupta India	14	37 0.1×	39 0.1×	116 0.3×	23 0.1×	30 0.1×	89	581

Countries citing papers authored by Peter J. Laud

Since Specialization

Citations

This map shows the geographic impact of Peter J. Laud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Laud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Laud more than expected).

Fields of papers citing papers by Peter J. Laud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Laud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Laud. The network helps show where Peter J. Laud may publish in the future.

Co-authorship network of co-authors of Peter J. Laud

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. Laud. A scholar is included among the top collaborators of Peter J. Laud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. Laud. Peter J. Laud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laud, Peter J., et al.. (2023). Thrombolysis Outcomes in Acute Ischaemic Stroke Patients with Pre-Existing Cognitive Impairment. Life. 13(4). 1055–1055. 1 indexed citations

Bell, Simon, Rohit Hariharan, Peter J. Laud, Arshad Majid, & Barbora de Courten. (2023). Carnosine supplementation improves delayed recall: a systematic review and meta‐analysis. Alzheimer s & Dementia. 19(S21).

He, Jianxing, Shugeng Gao, Martin Reck, et al.. (2023). OA12.06 Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN). Journal of Thoracic Oncology. 18(11). S72–S73. 7 indexed citations

Bell, Simon, Rohit Hariharan, Peter J. Laud, Arshad Majid, & Barbora de Courten. (2023). Histidine-containing dipeptide supplementation improves delayed recall: a systematic review and meta-analysis. Nutrition Reviews. 82(10). 1372–1385. 5 indexed citations

Hotta, Katsuyuki, Makoto Nishio, Haruhiro Saito, et al.. (2021). First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. International Journal of Clinical Oncology. 26(6). 1073–1082. 14 indexed citations

Giorgi, Mario, et al.. (2019). Effect of repeated in vivo microCT imaging on the properties of the mouse tibia. PLoS ONE. 14(11). e0225127–e0225127. 23 indexed citations

Baig, Sheharyar, Peter J. Laud, Muhammad Umar Farooq, et al.. (2019). Transcutaneous Auricular Vagus Nerve Stimulation with Upper Limb Repetitive Task Practice May Improve Sensory Recovery in Chronic Stroke. Journal of Stroke and Cerebrovascular Diseases. 28(12). 104348–104348. 49 indexed citations

Nishio, Makoto, Jun Ho Ji, Katsuyuki Hotta, et al.. (2019). Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia. Annals of Oncology. 30. ix197–ix198. 3 indexed citations

Redgrave, J.N., Douglas G. Day, Peter J. Laud, et al.. (2018). Safety and tolerability of Transcutaneous Vagus Nerve stimulation in humans; a systematic review. Brain stimulation. 11(6). 1225–1238. 201 indexed citations

10.

Armitage, Paul A., Peter J. Laud, Susan P. Mollan, et al.. (2018). Do Optic Canal Dimensions Measured on CT Influence the Degree of Papilloedema and Visual Dysfunction in Idiopathic Intracranial Hypertension?. Neuro-Ophthalmology. 43(1). 3–9. 9 indexed citations

11.

Qin, Xinyu, Min Ja Kim, Lie Wang, et al.. (2017). A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. International Journal of Antimicrobial Agents. 49(5). 579–588. 104 indexed citations

12.

Torres, Antoní, Nanshan Zhong, Jan Pachl, et al.. (2017). Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. The Lancet Infectious Diseases. 18(3). 285–295. 311 indexed citations

13.

Torres, Antoni, Ludmyla Rekeda, Xiang Chen, et al.. (2017). Phase 3, Randomized, Double-blind Noninferiority (NI) Study of Ceftazidime–Avibactam (CAZ-AVI) vs. Meropenem (MER) in the Treatment of Patients with Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP): Analyses of the REPROVE Study per US FDA Endpoints. Open Forum Infectious Diseases. 4(suppl_1). S535–S535. 6 indexed citations

14.

Laud, Peter J.. (2017). Equal‐tailed confidence intervals for comparison of rates. Pharmaceutical Statistics. 16(5). 334–348. 15 indexed citations

15.

Carmeli, Yehuda, J. Armstrong, Peter J. Laud, et al.. (2016). Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. The Lancet Infectious Diseases. 16(6). 661–673. 319 indexed citations

16.

Foxe, John J., et al.. (2012). Assessing the effects of caffeine and theanine on the maintenance of vigilance during a sustained attention task. Neuropharmacology. 62(7). 2320–2327. 82 indexed citations

17.

Camidge, D. Ross, K. Randall, John R. Foster, et al.. (2005). Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies. British Journal of Cancer. 92(10). 1837–1841. 17 indexed citations

18.

Camidge, D. Ross, M. N. Pemberton, J Growcott, et al.. (2005). Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development. British Journal of Cancer. 93(2). 208–215. 9 indexed citations

19.

Camidge, D. Ross, Michael Davies, Peter J. Laud, et al.. (2005). Factors determining the optimal body site and method for obtaining punch biopsies of human skin as a tissue in which to assess pharmacodynamic and pharmacokinetic endpoints in drug development studies. Cancer Chemotherapy and Pharmacology. 57(1). 52–58. 2 indexed citations

20.

Gerlag, Daniëlle M., Jasper J. Haringman, Tom Smeets, et al.. (2004). Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis & Rheumatism. 50(12). 3783–3791. 124 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact